While topical creams and treatments help on the surface, addressing hyperpigmentation at its root requires working at the cellular level
Tirzepatide reduced AHI by 29.3 events/hour, compared to a reduction of 5.5 events/hour with the placebo, for a treatment difference of 23.8 events/hour
Kim C, Lee SG, Yang WM, Arfuso F, Um JY, Kumar AP, et al
L.MorrisR
Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]